Asian Paints

2948.9 -19.60

Cipla

1511.2 -9.60

Eicher Motors

7190 -18.00

Nestle India

1235.1 -11.80

Grasim Inds

2748 1.00

Hindalco Inds.

827.35 4.10

Hind. Unilever

2335.5 -3.10

ITC

404.15 -0.80

Trent

4151.3 -31.80

Larsen & Toubro

4015.8 -22.40

M & M

3685.5 -31.60

Reliance Industr

1543.8 3.20

Tata Consumer

1161.2 -1.70

Tata Motors PVeh

352.55 -1.05

Tata Steel

166 -1.11

Wipro

261.32 1.41

Apollo Hospitals

7161.5 -28.00

Dr Reddy's Labs

1274.7 -0.50

Titan Company

3797.8 -15.50

SBI

963.8 -7.70

Shriram Finance

848.35 -6.55

Bharat Electron

394.65 -12.25

Kotak Mah. Bank

2153 -1.90

Infosys

1624.5 8.30

Bajaj Finance

1029.5 -18.50

Adani Enterp.

2250.7 -14.70

Sun Pharma.Inds.

1799 -6.30

JSW Steel

1147.5 -14.70

HDFC Bank

1003.2 -0.10

TCS

3251.9 13.70

ICICI Bank

1393 0.50

Power Grid Corpn

267.8 -2.00

Maruti Suzuki

16199 -83.00

Axis Bank

1273.3 -9.20

HCL Technologies

1691.3 8.30

O N G C

240.73 -0.50

NTPC

322.1 -1.20

Coal India

377.15 -2.80

Bharti Airtel

2094 -14.80

Tech Mahindra

1584.4 13.60

Jio Financial

300.85 -2.90

Adani Ports

1497.2 -12.20

HDFC Life Insur.

778.25 9.95

SBI Life Insuran

2028 4.30

Max Healthcare

1085.5 -11.90

UltraTech Cem.

11603 6.00

Bajaj Auto

9016.5 -92.50

Bajaj Finserv

2072.2 -24.30

Interglobe Aviat

5096.5 -274.00

Eternal Ltd

289.3 -3.10

IPO-Synopsis
Park Medi World Ltd
Initial public offer of up to [*] equity shares of face value of Rs. 2/- each ("Equity Shares") of Park Medi World Limited ("Company") for cash at a price of Rs. [*] per equity share (including a share premium of Rs. [*] per equity share) ("Offer Price") aggregating up to Rs. 920.00 crores comprising a fresh issue of up to [*] equity shares of face value of Rs. 2/- each aggregating up to Rs. 770.00 crores by the company ("Fresh Issue") and an offer for sale of up to [*] equity shares of face value of Rs. 2/- each aggregating up to Rs. 150.00 crores ("Offered Shares") by Ajit Gupta ("the Promoter Selling Shareholder") ("Offer for Sale", and together with the fresh issue, the "Offer"). The company, in consultation with the brlms, may consider an issue of specified securities, as may be permitted under applicable law, aggregating up to Rs. 192.00 crores prior to filing of the ("pre-ipo placement"). The pre-ipo placement, if undertaken, will be at a price to be decided by the company, in consultation with the brlms. if the pre-ipo placement is completed, the amount raised pursuant to the pre-ipo placement will be reduced from the fresh issue, subject to compliance with Rule 19(2)(b) of the securities contracts (Regulation) Rules, 1957, as amended. The pre-ipo placement, if undertaken, shall not exceed 20 % of the size of the fresh issue. Prior to the completion of the offer, the company shall appropriately intimate the subscribers to the pre-ipo placement, prior to allotment pursuant to the pre-ipo placement, that there is no guarantee that the company may proceed with the offer or the offer may be successful and will result into listing of the equity shares on the stock exchanges. Further, relevant disclosures in relation to such intimation to the subscribers to the pre-ipo placement (if Undertaken). The face value of equity shares is Rs. 2/- each. The offer price is [*] times the face value of the equity shares. Price Band: Rs. 154 to Rs. 162 per equity share of face value of Rs. 2 each. The floor price is 77 times of the face value and the cap price is 81 times of the face value of the equity shares. Bids can be made for a minimum of 92 equity shares and in multiples of 92 equity shares thereafter.
Issue
Opens On Closes On
10-Dec-25 12-Dec-25
Money Payable On
Application Allotment
154.00 0.00
Minimum Application for shares in Nos : 92 Further Multiples of : 92
Cr Lead Managers to the Issue
Project Cost (.Cr) 0.00 CLSA India Pvt ltd
Project Financed through Current Offer (.Cr) 920.00  
Post Issue Equity Share Capital (.Cr) 86.39
Issue Price () 154.00
Projects
Repayment/Prepayment in full or in part of certain outstanding borrowings availed by the company and certain of the company subsidiaries
Funding capital expenditure for development of new hospital by its Subsidiary Park Medicity (NCR)
Funding capital expenditure for purchase of medical equipment by the Company and its Subsidiaries, Blue Heavens and Ratangiri
General corporate purposes
Promoted By
Ajit Gupta
Ankit Gupta
Nidhi Gupta
Listing At
BSE
NSE
Registrar to the Issue
No Data Available

DJIA 47981.01
109.07 0.23%
S&P 500 6892.33
14.21 0.21%
HANG SENG 26085.09
149.18 0.58%
NIKKEI 225 50440.45
-587.97 -1.15%
FTSE 100 9667.01
-43.86 -0.45%
NIFTY 26097.80
-88.65 -0.34%
×
Ask Your Question
close
refresh